ARVN Q3 2025 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M-59.1% YoY

Gross Profit

$42M100.0% margin

Operating Income

-$44M-104.5% margin

Net Income

-$35M-83.8% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+87.1%

Cash Flow

Operating Cash Flow

-$59M

Free Cash Flow

-$59M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$844M

Total Liabilities

$280M

Stockholders' Equity

$564M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$102M	-59.1%
Gross Profit	$42M	$102M	-59.1%
Operating Income	-$44M	-$60M	+27.4%
Net Income	-$35M	-$49M	+28.7%

Revenue Segments

License

$130M100%